Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting
Background: Long-term efficacy of liraglutide, a glucagon-like peptide-1 analog, on body weight and glycemic control has not been studied in Indian Type 2 diabetes mellitus (T2DM) subjects. Aim: To evaluate the effect of liraglutide on glycemic control and body weight for 1 year in Indian T2DM patie...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2016;volume=20;issue=5;spage=595;epage=599;aulast=Kaur |
_version_ | 1811194245220925440 |
---|---|
author | Parjeet Kaur Shama Mahendru Ambrish Mithal |
author_facet | Parjeet Kaur Shama Mahendru Ambrish Mithal |
author_sort | Parjeet Kaur |
collection | DOAJ |
description | Background: Long-term efficacy of liraglutide, a glucagon-like peptide-1 analog, on body weight and glycemic control has not been studied in Indian Type 2 diabetes mellitus (T2DM) subjects. Aim: To evaluate the effect of liraglutide on glycemic control and body weight for 1 year in Indian T2DM patients. Methods: Liraglutide was prescribed to 96 obese patients with T2DM and followed up for 1 year. Clinical parameters were measured at baseline and 3, 6, 9, and 12 months. Dosage of liraglutide and other medications was adjusted according to clinical judgment. Results: 1 year data were available for 74 patients. Mean age was 50.9 ± 9.6 years. Mean duration of diabetes was 11.6 ± 6.3 years. Glycosylated hemoglobin (HbA1c) significantly decreased from 8.9 ± 1.3% at baseline to 7.4 ± 1.2% at 1 year. Body weight significantly declined from 98.9 ± 16.0 kg at baseline to 93.8 ± 15.0 kg at 1 year. After an initial decline, subset of patients had an increase in mean HbA1c (n = 30/74) and mean body weight (n = 33/74) after 6 months of liraglutide initiation. Baseline HbA1c and baseline body weight were positively associated with a reduction of HbA1c and body weight at 1 year, respectively. No major side effects occurred. Conclusion: Liraglutide treatment resulted in a significant and sustained reduction in HbA1c and body weight over 1 year in Indian T2DM patients. Magnitude of reduction of HbA1c and body weight at 1 year was positively associated with baseline HbA1c and baseline weight, respectively. |
first_indexed | 2024-04-12T00:23:41Z |
format | Article |
id | doaj.art-c842a2b768dc4ba3aa3bc1cd874a9d4a |
institution | Directory Open Access Journal |
issn | 2230-8210 |
language | English |
last_indexed | 2024-04-12T00:23:41Z |
publishDate | 2016-01-01 |
publisher | Wolters Kluwer Medknow Publications |
record_format | Article |
series | Indian Journal of Endocrinology and Metabolism |
spelling | doaj.art-c842a2b768dc4ba3aa3bc1cd874a9d4a2022-12-22T03:55:39ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102016-01-0120559559910.4103/2230-8210.183825Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world settingParjeet KaurShama MahendruAmbrish MithalBackground: Long-term efficacy of liraglutide, a glucagon-like peptide-1 analog, on body weight and glycemic control has not been studied in Indian Type 2 diabetes mellitus (T2DM) subjects. Aim: To evaluate the effect of liraglutide on glycemic control and body weight for 1 year in Indian T2DM patients. Methods: Liraglutide was prescribed to 96 obese patients with T2DM and followed up for 1 year. Clinical parameters were measured at baseline and 3, 6, 9, and 12 months. Dosage of liraglutide and other medications was adjusted according to clinical judgment. Results: 1 year data were available for 74 patients. Mean age was 50.9 ± 9.6 years. Mean duration of diabetes was 11.6 ± 6.3 years. Glycosylated hemoglobin (HbA1c) significantly decreased from 8.9 ± 1.3% at baseline to 7.4 ± 1.2% at 1 year. Body weight significantly declined from 98.9 ± 16.0 kg at baseline to 93.8 ± 15.0 kg at 1 year. After an initial decline, subset of patients had an increase in mean HbA1c (n = 30/74) and mean body weight (n = 33/74) after 6 months of liraglutide initiation. Baseline HbA1c and baseline body weight were positively associated with a reduction of HbA1c and body weight at 1 year, respectively. No major side effects occurred. Conclusion: Liraglutide treatment resulted in a significant and sustained reduction in HbA1c and body weight over 1 year in Indian T2DM patients. Magnitude of reduction of HbA1c and body weight at 1 year was positively associated with baseline HbA1c and baseline weight, respectively.http://www.ijem.in/article.asp?issn=2230-8210;year=2016;volume=20;issue=5;spage=595;epage=599;aulast=KaurDiabetesIndialiraglutideobesity |
spellingShingle | Parjeet Kaur Shama Mahendru Ambrish Mithal Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting Indian Journal of Endocrinology and Metabolism Diabetes India liraglutide obesity |
title | Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting |
title_full | Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting |
title_fullStr | Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting |
title_full_unstemmed | Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting |
title_short | Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting |
title_sort | long term efficacy of liraglutide in indian patients with type 2 diabetes in a real world setting |
topic | Diabetes India liraglutide obesity |
url | http://www.ijem.in/article.asp?issn=2230-8210;year=2016;volume=20;issue=5;spage=595;epage=599;aulast=Kaur |
work_keys_str_mv | AT parjeetkaur longtermefficacyofliraglutideinindianpatientswithtype2diabetesinarealworldsetting AT shamamahendru longtermefficacyofliraglutideinindianpatientswithtype2diabetesinarealworldsetting AT ambrishmithal longtermefficacyofliraglutideinindianpatientswithtype2diabetesinarealworldsetting |